BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 12775278)

  • 1. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
    Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
    Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
    Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
    Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
    Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
    Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
    Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
    Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark.
    Jønler M; Eddy B; Poulsen J
    Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
    Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
    BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
    Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
    Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographical variation in incidence of prostate cancer in Sweden.
    Stattin P; Johansson R; Lodnert R; Andrén O; Bill-Axelsson A; Bratt O; Damber JE; Hellström M; Hugosson J; Lundgren R; Törnblom M; Varenhorst E; Johansson JE
    Scand J Urol Nephrol; 2005; 39(5):372-9. PubMed ID: 16257838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
    Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
    J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Misclassifying the indications for prostate-specific antigen testing may bias case-control studies of the efficacy of prostate cancer screening.
    Hoffman RM; Adams-Cameron ML; Murata GH
    J Clin Epidemiol; 2004 Oct; 57(10):1071-5. PubMed ID: 15528058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
    Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
    BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA testing in Austria: induced morbidity and saved mortality.
    Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
    Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.